Literature DB >> 8353282

Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency.

J Conard1, K A Bauer, A Gruber, J H Griffin, H P Schwarz, M H Horellou, M M Samama, R D Rosenberg.   

Abstract

Homozygous or double heterozygous protein-C deficiency can present at birth with purpura fulminans or later in life with venous thrombosis. Two homozygous patients who had previously sustained thrombotic episodes were investigated at a time when they were asymptomatic and not receiving antithrombotic therapy. The plasma levels of protein-C antigen and activity in both individuals were approximately 20% of normal. We administered a highly purified plasma-derived protein C concentrate to these individuals and monitored levels of several markers of in vivo coagulation activation. Assays for protein-C activation (activated protein C and protein C activation peptide) showed a sustained increase from reduced baseline levels, whereas thrombin generation (as measured by prothrombin fragment F1 + 2) gradually decreased over about 24 hours into the normal range. These investigations provide direct evidence that protein C is converted to activated protein C in vivo, and that the protein-C anticoagulant pathway is a tonically active mechanism in the regulation of hemostatic system activation in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353282

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.

Authors:  H Weiler-Guettler; P D Christie; D L Beeler; A M Healy; W W Hancock; H Rayburn; J M Edelberg; R D Rosenberg
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

2.  Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.

Authors:  F M Müller; W Ehrenthal; G Hafner; D Schranz
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

3.  Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va.

Authors:  A J Gale; X Sun; M J Heeb; J H Griffin
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

4.  Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Authors:  Sabine Kroiss; Manuela Albisetti
Journal:  Biologics       Date:  2010-03-24

5.  Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.

Authors:  S R Cai; S C Kennedy; W M Bowling; M W Flye; K P Ponder
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

6.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.